Ractigen Therapeutics
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2016-09-02
- Employees
- 51
- Market Cap
- -
- Website
- https://www.ractigen.com
Ractigen Therapeutics Doses First Patient in Phase I Trial of RAG-17 for SOD1-Related ALS
Ractigen Therapeutics has dosed the first patient in a Phase I clinical trial of RAG-17, a siRNA therapy for ALS patients with SOD1 mutations.
Ractigen's RAG-21 Receives FDA Orphan Drug Designation for FUS-ALS Treatment
Ractigen Therapeutics' RAG-21, a novel siRNA therapy targeting the FUS gene, has received FDA Orphan Drug Designation for amyotrophic lateral sclerosis (ALS).
FDA Grants Orphan Drug Designation to Ractigen's RAG-21 for FUS-ALS
The FDA has granted Orphan Drug Designation to Ractigen Therapeutics' RAG-21 for amyotrophic lateral sclerosis (ALS) treatment, specifically targeting the FUS subtype.
Ractigen's RAG-18 Receives FDA Orphan Drug Designation for Duchenne and Becker Muscular Dystrophy
Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) therapy, has been granted Orphan Drug Designation by the FDA for treating Duchenne and Becker muscular dystrophy.
© Copyright 2025. All Rights Reserved by MedPath